Common Contracts
1 similar null contracts
Sumitovant Enters into an Agreement for “Going Private” TransactionNovember 13th, 2020
Sumitovant Biopharma Ltd. (“Sumitovant”), a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura, “Sumitomo Dainippon Pharma”), and Urovant Sciences Ltd.(“Urovant”), consolidated subsidiary of Sumitomo Dainippon Pharma, announced on November 12 (local time) that they have entered into a definitive agreement where Sumitovant would make Urovant its wholly-owned subsidiary (the “Transaction”) as follows.
